← Holders
DAFNA Capital Management LLC
What DAFNA Capital Management LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1389933 · Filed Nov 16, 2026
- Positions
- 87
- Reported value
- $468.1M
- Opened
- 5
- Closed
- 6
- Other managers included
- 1
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$404.8M75 positions
- Dec 31, 2025$430.5M77 positions
- Mar 31, 2026$439.6M83 positions
- Jun 30, 2026$524.4M88 positions
- Sep 30, 2026$468.1M87 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
RVMDRevolution Medicines, Inc. | 487.1K | −13.4% | $100M | 21.4% |
ATRCAtriCure, Inc. | 522.7K | −12.5% | $29.4M | 6.3% |
CMPSCOMPASS Pathways plc | 2.1M | +6.2% | $26.6M | 5.7% |
SPDR S&P BIOTECH ETFETF | 151.5K | −22.9% | $23.9M | 5.1% |
NKTRNektar Therapeutics | 323.4K | +1.6% | $19.6M | 4.2% |
IDYAIDEAYA Biosciences, Inc. | 438.7K | −11.8% | $16.9M | 3.6% |
STXSStereotaxis, Inc. | 13.7M | ±0% | $16.8M | 3.6% |
DNLIDenali Therapeutics Inc. | 744K | +0.7% | $15.4M | 3.3% |
ASNDAscendis Pharma A/S | 50K | +3.1% | $11.4M | 2.4% |
RCUSArcus Biosciences, Inc. | 439.8K | −0.5% | $11.4M | 2.4% |
CYTKCytokinetics Inc | 172K | ±0% | $11.3M | 2.4% |
EWTXEdgewise Therapeutics, Inc. | 221.8K | −2.2% | $9M | 1.9% |
NBIXNeurocrine Biosciences Inc | 62.7K | +8.6% | $8.9M | 1.9% |
PODDInsulet Corp | 67.9K | +9.7% | $8.9M | 1.9% |
XENEXenon Pharmaceuticals Inc. | 204.8K | −18.3% | $7.6M | 1.6% |
AXGNAxogen, Inc. | 180K | −13.9% | $7.5M | 1.6% |
DXCMDexCom Inc | 86.3K | ±0% | $7.4M | 1.6% |
SNDXSyndax Pharmaceuticals Inc | 331.3K | −1.2% | $6.2M | 1.3% |
LRMRLarimar Therapeutics, Inc. | 1.9M | −6.0% | $6M | 1.3% |
TNDMTandem Diabetes Care Inc | 355.2K | New | $5.8M | 1.2% |
BCAXBicara Therapeutics Inc. | 300K | +5.3% | $5.6M | 1.2% |
RAPPRapport Therapeutics, Inc. | 141.9K | +89.2% | $4.8M | 1% |
IMVTImmunovant, Inc. | 135.5K | −9.4% | $4.6M | 1% |
INGNInogen Inc | 845.2K | ±0% | $4.5M | 1% |
NGNENeurogene Inc. | 150.5K | +69.1% | $4.2M | 0.9% |
ALKSAlkermes plc. | 101.3K | ±0% | $4.1M | 0.9% |
IPSCCentury Therapeutics, Inc. | 2.4M | −0.6% | $4.1M | 0.9% |
KIDSOrthopediatrics Corp | 179.1K | −5.3% | $4M | 0.9% |
LKFTLakefront Biotherapeutics NV | 130.2K | ±0% | $3.9M | 0.8% |
STOKStoke Therapeutics, Inc. | 146.1K | +11.7% | $3.8M | 0.8% |
ANLAdlai Nortye Group Ltd. | 232.8K | −2.8% | $3.7M | 0.8% |
EPRXEupraxia Pharmaceuticals Inc. | 404.6K | +79.3% | $3.7M | 0.8% |
CLDXCelldex Therapeutics, Inc. | 108.1K | +57.8% | $3.5M | 0.7% |
ALLOAllogene Therapeutics, Inc. | 2M | ±0% | $3.2M | 0.7% |
BCRXBiocryst Pharmaceuticals Inc | 380.2K | −5.0% | $3.2M | 0.7% |
KYMRKymera Therapeutics, Inc. | 26.9K | −0.3% | $3M | 0.6% |
AQSTAquestive Therapeutics, Inc. | 640.9K | −0.8% | $3M | 0.6% |
RNAAtrium Therapeutics, Inc. | 300.1K | +134.4% | $2.5M | 0.5% |
ISHARES NASDAQ BIOTECH INDXETF | 11.6K | −72.8% | $2.4M | 0.5% |
PRCTPROCEPT BioRobotics Corp | 120K | ±0% | $2.2M | 0.5% |
PRQRProQR Therapeutics N.V. | 1.3M | −14.2% | $2.2M | 0.5% |
HELPHelus Pharma Inc. | 175.7K | −65.8% | $2.2M | 0.5% |
ALGNAlign Technology Inc | 14K | ±0% | $2M | 0.4% |
VKTXViking Therapeutics, Inc. | 54.5K | −8.4% | $1.8M | 0.4% |
MAZEMaze Therapeutics, Inc. | 65K | ±0% | $1.8M | 0.4% |
ALECAlector, Inc. | 908.4K | ±0% | $1.7M | 0.4% |
TELATELA Bio, Inc. | 1.4M | ±0% | $1.7M | 0.4% |
MPLTMapLight Therapeutics, Inc. | 155.6K | −9.0% | $1.6M | 0.3% |
NGENNervgen Pharma Corp. | 810.9K | −22.8% | $1.5M | 0.3% |
GPCRStructure Therapeutics Inc. | 46.5K | ±0% | $1.5M | 0.3% |
PROFProfound Medical Corp. | 225.1K | −13.5% | $1.3M | 0.3% |
MDWDMediWound Ltd. | 94.4K | ±0% | $1.3M | 0.3% |
DSGNDesign Therapeutics, Inc. | 102.1K | −0.5% | $1.3M | 0.3% |
LXEOLexeo Therapeutics, Inc. | 377.1K | ±0% | $1.3M | 0.3% |
INSPInspire Medical Systems, Inc. | 18.2K | ±0% | $1.3M | 0.3% |
CTMXCytomX Therapeutics, Inc. | 438.4K | ±0% | $1.2M | 0.3% |
FATEFate Therapeutics Inc | 500K | −4.8% | $1.2M | 0.3% |
MLYSMineralys Therapeutics, Inc. | 44.5K | ±0% | $1.1M | 0.2% |
PYPDPolyPid Ltd. | 207.9K | ±0% | $1.1M | 0.2% |
BBOTBridgeBio Oncology Therapeutics, Inc. | 266K | New | $1.1M | 0.2% |
ANNXAnnexon, Inc. | 257.6K | −13.5% | $1.1M | 0.2% |
BHVNBiohaven Ltd. | 77.6K | −43.6% | $1M | 0.2% |
IMTXImmatics N.V. | 117K | ±0% | $1M | 0.2% |
QTTBQ32 Bio Inc. | 98.5K | +199.4% | $814.6K | 0.2% |
PYXSPyxis Oncology, Inc. | 344.8K | New | $803.4K | 0.2% |
SPRYARS Pharmaceuticals, Inc. | 182.8K | +11.3% | $787.8K | 0.2% |
RAREUltragenyx Pharmaceutical Inc. | 51.1K | +8.5% | $768K | 0.2% |
KURAKura Oncology, Inc. | 69.1K | −42.7% | $739.7K | 0.2% |
BNTXBioNTech SE | 7K | ±0% | $688.1K | 0.1% |
SCYXScynexis Inc | 135.9K | ±0% | $671.2K | 0.1% |
ACETAdicet Bio, Inc. | 93.8K | ±0% | $669.8K | 0.1% |
SPTXSeaport Therapeutics, Inc. | 32.4K | ±0% | $653.5K | 0.1% |
QNRXQuoin Pharmaceuticals Ltd. | 132.2K | New | $602.6K | 0.1% |
CRBPCorbus Pharmaceuticals Holdings, Inc. | 83.2K | −22.8% | $567.8K | 0.1% |
PLRXPliant Therapeutics, Inc. | 487K | ±0% | $526K | 0.1% |
EDITEditas Medicine, Inc. | 180.5K | +5.9% | $463.8K | 0.1% |
ARAYAccuray Inc | 1.7M | ±0% | $453.9K | 0.1% |
CGENCompugen Ltd | 168.2K | ±0% | $400.4K | 0.1% |
AUTLAutolus Therapeutics plc | 179.3K | ±0% | $347.9K | 0.1% |
FHTXFoghorn Therapeutics Inc. | 89.7K | −19.8% | $320.1K | 0.1% |
IBIOiBio, Inc. | 170.1K | ±0% | $200.7K | 0.1% |
TNYATenaya Therapeutics, Inc. | 300K | ±0% | $181.1K | 0.1% |
KZIAKazia Therapeutics Ltd | 15.7K | New | $150.6K | 0.1% |
ENGNenGene Therapeutics Inc. | 74.7K | ±0% | $149.3K | 0.1% |
VRCAVerrica Pharmaceuticals Inc. | 23.8K | ±0% | $113.9K | 0.1% |
KARDKardigan, Inc. | 5K | ±0% | $73.8K | 0.1% |
ADCTADC Therapeutics SA | 57.1K | −25.9% | $69.6K | 0.1% |